Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Comments

Loading...

Transgene Stock News

TRGNFOTCEM

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Perks Buy Compare Brokers

$0.7000

Last update: Dec 31, 7:00 PM

Transgene (TRGNF) Forecast

News

Earnings Transgene (TRGNF) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest Transgene Stock News | OTC:TRGNF | Benzinga

Get the latest news on Transgene stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Transgene performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, May 05, 2023

AstraZeneca Terminated Its Oncolytic Virus Research And Development Collaboration With Transgene Signed In 2019; Transgene Will Regain Global Rights To The Oncolytic Virus Drug Candidate That Was Licensed By AstraZeneca In December 2021
Charles Gross

Tuesday, February 25, 2020

Stocks That Hit 52-Week Lows On Tuesday
Lisa Levin

Monday, August 05, 2019

New 52-Week Lows For Monday Morning
Lisa Levin

Tuesday, July 23, 2019

List of Companies Reaching Yearly Lows Tuesday
Lisa Levin

Thursday, May 02, 2019

Transgene, Astrazeneca Enter Collaboration, Exclusive License Option Agreement for Innovative Invir.iotm Based Armed Oncolytic Immunotherapies
Charles Gross

Tuesday, April 25, 2017

Transgene, Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line NSCLC
Benzinga

Monday, June 01, 2015

Transgene Presents Positive New Results at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in NSCLC
Benzinga

Wednesday, January 29, 2014

Sanofi, Transgene Launch Construction Phase of Bioproduction Platform
Benzinga

Popular Channels

PreMarket Playbook
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved